Methods of Inhibiting Diseases Caused by Respiratory Viruses

1 . A method of treating a viral respiratory disease, comprising:

administering to a subject, in need thereof, an effective amount of L. reuteri strain 3632 and/or strain 3630, wherein L. reuteri strain 3632 and/or strain 3630 secrete mersacidin.

2 . A method according to claim 1 wherein L. reuteri strain 3632 and/or strain 363 is administered by probiotic composition.

3 . A method according to claim 1 wherein L. reuteri strain 3632 and/or strain 363 is administered by a live delivery platform.

4 . The method according to claim 2 wherein the administration is oral, by inhalation, intravenous, subcutaneous, intramuscular or mucosal.

5 . The method according to claim 1 , wherein the disease is caused by a corona virus or influenza virus.

6 . The method according to claim 5 , wherein the corona virus is selected from the group consisting of alpha coronaviruses, the beta coronaviruses, MERS-COV, SAR-CoV, SARS-COV-2 and the common cold.

7 . A method of treating a viral respiratory disease, comprising:

systemically administering to a subject, in need thereof, a pharmaceutical composition comprising an effective amount of mersacidin.

8 . The method according to claim 7 wherein the administration is oral, by inhalation, intravenous, subcutaneous, intramuscular or mucosal.

9 . The method according to claim 7 , wherein the disease is caused by a corona virus or influenza virus.

10 . A method of treating gut dysbiosis, comprising:

administering to a subject, in need thereof, an effective amount of L. reuteri strain 3632 and/or strain 3630, wherein L. reuteri strain 3632 and/or strain 3630 secrete mersacidin.

11 . A method according to claim 10 wherein L. reuteri strain 3632 and/or strain 363 is administered by probiotic composition.

12 . A method according to claim 10 wherein L. reuteri strain 3632 and/or strain 363 is administered by a live delivery platform.